
    
      This study will investigate the efficacy of ASP3652 in the treatment of patients with Chronic
      abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS). In comparison with placebo,
      ASP3652 will be given in different dosages orally for 12 weeks. The aims are to investigate
      efficacy of ASP3652 in CP/CPPS, to assess the optimal dose of ASP3652, to investigate safety
      and tolerability and to investigate pharmacokinetics and pharmacodynamics of ASP3652 in
      patients with CP/CPPS in and out-patients setting.
    
  